Fri.Jan 26, 2024

article thumbnail

Merck's Keytruda extends life for kidney cancer patients after surgery, while Bristol's Opdivo fails again

Fierce Pharma

Merck’s unique approval for Keytruda as a postsurgical treatment for resectable kidney cancer has gained new backing in the form of data showing the PD-1 inhibitor can extend patients’ lives. | Merck’s unique approval for Keytruda as a postsurgerical treatment for resectable kidney cancer has gained new backing in the form of data showing the PD-1 inhibitor can extend patients’ lives.

Patients 328
article thumbnail

Adverse Event Reports Linked to Counterfeit Ozempic on the Rise

Pharmaceutical Commerce

Concerns regarding hypoglycemia potentially linked to a counterfeit version of Ozempic come at a time in which reports have grown regarding the improper use of GLP-1 receptor agonists for the purpose of cosmetic weight loss.

115
115
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

J&J, Merck CEOs dodge subpoenas by agreeing to testify at Senate committee's pricing hearing

Fierce Pharma

With the unusual threat of a Senate subpoena hanging over their heads, the CEOs of Johnson & Johnson and Merck & Co. | With the unusual threat of a Senate subpoena hanging over their heads, the CEOs of Johnson & Johnson and Merck & Co. have agreed to join their counterpart at Bristol Myers Squibb in testifying before the Senate Committee on Health, Education, Labor and Pensions (HELP).

Education 294
article thumbnail

ArriVent’s Nasdaq Debut Nabs $175M as Signs Indicate an Opening IPO Window

MedCity News

ArriVent BioPharma will apply the IPO cash toward furmonertinib, which the biotech says could offer advantages over Takeda Pharmaceutical and Johnson & Johnson drugs that address the same lung cancer target. It’s the second biotech IPO of this week, following CG Oncology.

Biopharma 116
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

AbbVie pumps $223M into Singapore biologics plant, plots 100 hires

Fierce Pharma

In late 2022, GSK, Sanofi and Takeda signed on with a partnership of local agencies to advance biologic manufacturing in Singapore. | In late 2022, GSK, Sanofi and Takeda signed on with a partnership of local agencies to advance biologic manufacturing in Singapore. Now, a little more than a year later, AbbVie is getting in on the action by starting a major production expansion in the Garden City.

article thumbnail

How Are Payers Approaching Obesity Management?

MedCity News

GLP-1s continue to be in high demand, and the healthcare industry is watching closely to see how payers decide to cover the drugs going forward. During a virtual panel, payer executives noted that it’s important to remember that GLP-1s won’t be able to solve the country’s obesity crisis by themselves.

More Trending

article thumbnail

Mitotic Counting Reimagined: When AI Meets the Microscope

MedCity News

The shift towards digital pathology has marked a significant advancement in breast cancer diagnosis. High-resolution digital imaging of slides provides pathologists with an unprecedentedly clear and expansive view of tissue samples for their analysis.

Biopharma 108
article thumbnail

Sanofi and Regeneron's Dupixent picks up FDA nod to treat kids with eosinophilic esophagitis

Fierce Pharma

At Sanofi and Regeneron, it’s all about the kids—at least with respect to their recent advancements of anti-inflammatory powerhouse Dupixent. | The FDA has signed off on Sanofi and Regeneron's Dupixent to treat children between the ages of 1 and 11 who weigh at least 33 pounds with eosinophilic esophagitis. Dupixent becomes the first treatment in the U.S. for children in this age group with the disorder.

FDA 253
article thumbnail

Eosinophilic esophagitis medicine approval expanded

European Pharmaceutical Review

The US Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) as a treatment for children patients aged one to 11 years, weighing at least 15kg with eosinophilic esophagitis (EoE). This new authorisation by the FDA’s expands its initial approval for EoE in May 2022 for patients aged 12 years and older, weighing at least 40kg. “With this approval, Dupixent becomes the first and only treatment option for EoE patients aged one year and older, weighing at least 15kg” “With this

article thumbnail

Bristol Myers wins, Apellis loses in busy week at Europe's drug regulator

Fierce Pharma

Shortly after Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended refusal of a marketing authorization | Shortly after Europe’s Committee for Medicinal Products for Human Use (CHMP) recommended refusal of marketing authorization for Apellis’ geographic atrophy (GA) drug Syfovre (pegcetacoplan injection), the company said it will appeal the guidance.

Medicine 247
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Key vaccine adjuvant biosynthesised

European Pharmaceutical Review

A paper, published in Nature Chemical Biology has reported the first ‘free-from ‘tree’ production of a key vaccine ingredient sourced from the soapbark tree. Researchers from the John Innes Centre, a research institute in the UK, have reconstituted the chemical pathway of the potent adjuvant molecule QS-21 in a tobacco plant. Bioengineering vaccine adjuvants The paper explained: “QS-21 is a potent vaccine adjuvant currently sourced by extraction from the Chilean soapbark tree.

article thumbnail

Bristol Myers reveals subcutaneous Opdivo data in kidney cancer as I-O battle heads to new front

Fierce Pharma

Bristol Myers Squibb is offering a detailed look at pivotal data showing that an under-the-skin version of its PD-1 inhibitor Opdivo works as well as the original intravenous formulation in kidney | Bristol Myers Squibb is offering a detailed look at pivotal data showing an under-the-skin version of its PD-1 inhibitor Opdivo works as well as the original intravenous formulation in kidney cancer.

129
129
article thumbnail

Does Patient Priorities Care Result in Better Outcomes for Patients?

Pharmaceutical Commerce

A non-randomized control trial investigates whether older adults with multiple chronic conditions can benefit by receiving more specialized services.

Patients 103
article thumbnail

‘The Top Line’: Closing the $1 trillion women’s health gap

Fierce Pharma

‘The Top Line’: Closing the $1 trillion women’s health gap aellison Fri, 01/26/2024 - 09:55

144
144
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

CAR-T therapies and cancer risk: No easy answers for the FDA

Pharmaceutical Technology

CAR-T cell therapies can provide durable cancer remission, however, a recent FDA investigation into reports of secondary T-cell malignancies has increased scrutiny of their risk profiles.

FDA 87
article thumbnail

#PIDfest – Bringing the PID Community Back Together Again!

Copyright Clearance Center

There's a new PID conference in town - PIDfest will take place at the Czech National Library of Technology in Prague on June 11-13, 2024.

article thumbnail

UnitedHealthcare Launches Resource To Help Members Access Health Programs

MedCity News

UnitedHealthcare recently launched UHC Hub, which helps self-funded employers manage multiple health solutions and employees gain access to these solutions.

article thumbnail

AbbVie invests $223m in Singapore biologics site

pharmaphorum

AbbVie has broken ground on a new $223 million expansion of its biologics manufacturing facility in Singapore, creating around 100 new jobs

article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

BHF data reveals early heart disease deaths rise to highest level

PharmaTimes

In 2022, over 39,000 people in England died prematurely of cardiovascular conditions

article thumbnail

Britain will be first to get new Mounjaro device, says Lilly

pharmaphorum

Eli Lilly is weeks away from launching Mounjaro in the UK, after getting approval from the MHRA for a multi-dose injector version for diabetes and obesity

93
article thumbnail

NHS urges more young people to take up HPV vaccine

PharmaTimes

HPV is a common group of viruses which can sometimes lead to cancer

Leads 97
article thumbnail

New NHS trust should oversee, sell patient data, says report

pharmaphorum

Report on UK biotech sector by Tony Blair and William Hague calls for an NHS trust to be set up to oversee and sell patient data

article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Atossa Therapeutics progresses Phase II preventative breast cancer therapy

Pharmaceutical Technology

Atossa Therapeutics estimates a Q3 Phase II readout for Z-endoxifen, as it plans a Phase III preventative breast cancer trial.

64
article thumbnail

Then there were two: ArriVent set to list after $175m IPO

pharmaphorum

ArriVent BioPharma completes the second biotech IPO of 2024, raising $175m that will help advance its late-stage lung cancer drug furmonertinib

article thumbnail

Breaking the Chains of Opioid Addiction: The Promise of Long-Acting Injectables

Pharmaceutical Commerce

As providers and healthcare professionals recognize the potential of long-acting injectables to fight the opioid epidemic, many are actively transitioning from oral options to injectables.

article thumbnail

Recent Licensing Agreement Poised to Advance Company ADC

PharmExec

In an interview with PharmExec Associate Editor Don Tracy, Jingsong Wang discusses Nona Biosciences’ recent exclusive license agreement with Pfizer Inc. for the development and commercialization of HBM9033.

52
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Meet Our Mentor: Mat Pfeffer

MedTechVets

JAN 26th – We were proud to interview MedTechVet Academy Mentor, Mat Pfeffer. Mat the Director of Image Guided Therapy Devices at Philips. “It’s important to have pride in your job. Obviously, nothing will top the pride of serving in the U.S. Marine Corps for 22 years, so when it came time to retire from the military and pursue my next venture, I knew it would be important to have pride in my job, my company, and my industry.

article thumbnail

Drug shortages challenge type 2 diabetes patients in the UK

Pharmaceutical Technology

Type-2 diabetes patients continue to be impacted by GLP-1 RA drug shortages in the UK with an NHS alert issuing guidelines on drug substitutions.

article thumbnail

Challenges and Benefits of Implementing IDMP in the Pharmaceutical Industry

Pharmaceutical Commerce

The Identification of Medicinal Product framework seeks to establish a common language for identifying, documenting, and exchanging information about medicinal products.

article thumbnail

‘1 plus 1 equals 3’ — the co-CEO model in pharma

PharmaVoice

Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.

Pharma 52
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A